GHRP-2 - Livewell Pharmaceuticals

GHRP-2, known generically as pralmorelin, was first introduced in 1993 by Dr. C.Y. Bowers at Tulane University, a major figure in GH secretagogue research. Developed in partnership with Kaken Pharmaceuticals, it became the next-generation peptide after GHRP-6, designed for greater GH stimulation and less appetite activation. GHRP-2 gained approval in Japan in 2005 under the name GHRP Kaken 100 Injection, specifically for diagnosing growth hormone deficiency. It was later granted orphan drug status in the U.S. in 2012, further cementing its place in the GH-therapy landscape​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about GHRP-2 by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.